Related Experiment Video
Updated: Aug 10, 2026

Modification of the Treatment Methods for Wasting Marmoset Syndrome with Tranexamic Acid and Supportive Measures
Published on: July 12, 2024
[Managing methotrexate toxicity: a case report]
M J Fernández Megía1, M Alós Almiñana, M J Terol Castera
1Servicio de Farmacia, Hospital Virgen de la Luz, Cuenca.
Abstract:
High-dose methotrexate is included in chemotherapy regimens used to treat a number of malignant neoplasms. Methotrexate plasma concentration is considered the best toxicity predictor. Monitoring methotrexate plasma concentrations is standard practice in the identification of at-risk patients, the titration of folinic acid doses, and the establishment of corrective measures. Methotrexate is a kidney-cleared weak acid, and renal function impairment may retard methotrexate clearance. A case of severe methotrexate-induced toxicity secondary to renal failure is reported in a patient with non-Hodgkin s lymphoma receiving methotrexate at a dose of 1 g/m2. Corrective measures included folinic acid rescue therapy, cholestyramine resin administration, hydration and urine alkalinization, urine pH monitoring, and extracorporeal clearance techniques.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Therapeutic Drug Monitoring: Affecting Factors
Drug Toxicity: Risk factors
Drug toxicity: Drug–Drug Interaction
Pharmaceutical Poisoning: Treatment Strategies
Myocarditis IV: Nursing Management